The association between tumor mutational burden and prognosis is dependent on treatment context
暂无分享,去创建一个
V. Seshan | M. Ladanyi | M. Berger | G. Plitas | A. Hakimi | T. Chan | D. Solit | I. Ganly | Mark Lee | R. Samstein | A. Shoushtari | A. Zehir | R. Wong | N. Riaz | M. Postow | A. Crago | Satshil Rana | Douglas R. Hoen | V. Balachandran | L. Morris | Z. Nadeem | Jingming Wang | K. L. Long Roche | C. Valero | D. Kelly | Neal Patel | J. Smith | T. Chan
[1] Tao Wang,et al. DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden , 2020, Cell reports medicine.
[2] Nicolai J. Birkbak,et al. The T cell differentiation landscape is shaped by tumour mutations in lung cancer , 2020, Nature Cancer.
[3] M. Hernán,et al. Why Test for Proportional Hazards? , 2020, JAMA.
[4] Huiyan Luo,et al. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. , 2019, Annals of translational medicine.
[5] Ruizhu Zheng,et al. Correlations between microsatellite instability and the biological behaviour of tumours , 2019, Journal of Cancer Research and Clinical Oncology.
[6] M. Rubin,et al. Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution. , 2019, JCO precision oncology.
[7] V. Budach,et al. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. , 2019, European journal of cancer.
[8] A. Gonzalez-Perez,et al. The mutational footprints of cancer therapies , 2019, bioRxiv.
[9] J. Nieva,et al. Impact of prior chemotherapy or radiation therapy on tumor mutation burden in NSCLC. , 2019, Journal of Clinical Oncology.
[10] C. Brennan,et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.
[11] A. Niemierko,et al. Clinical Impact of Tumor Mutational Burden in Neuroblastoma. , 2018, Journal of the National Cancer Institute.
[12] Yuki Matsumura,et al. Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non–Small Cell Lung Cancer: Brief Report , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] Reporting for specific materials, systems and methods , 2018 .
[14] Ahmet Zehir,et al. Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. , 2017, JCO precision oncology.
[15] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[16] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[17] M. Berger,et al. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma , 2017, Clinical Cancer Research.
[18] Jay Shendure,et al. Classification and characterization of microsatellite instability across 18 cancer types , 2016, Nature Medicine.
[19] In-Hee Lee,et al. Clonal evolution of glioblastoma under therapy , 2016, Nature Genetics.
[20] J. Reis-Filho,et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival , 2016, Oncotarget.
[21] Hanlee P. Ji,et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.
[22] S. Gabriel,et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.
[23] Jens Schreiner,et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors , 2015, Cancer Immunology Research.
[24] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[25] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[26] Krishnendu Chatterjee,et al. Evolutionary dynamics of cancer in response to targeted combination therapy , 2013, eLife.
[27] R. Houlston,et al. Systematic review of microsatellite instability and colorectal cancer prognosis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Martin A. Nowak,et al. The role of chromosomal instability in tumor initiation , 2002, Proceedings of the National Academy of Sciences of the United States of America.